Herriot Tabuteau, Axsome CEO (Photo by Owen Hoffmann/Patrick McMullan via Getty Images)

February 27, 2023 10:10 AM EST

Axsome says FDA wants more data for Alzheimer’s agitation label expansion, but readout to come sooner

Axsome Therapeutics said the FDA wants safety information from the biotech’s third Phase III study of its drug candidate for Alzheimer …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ax­some says FDA wants more da­ta for Alzheimer’s ag­i­ta­tion la­bel ex­pan­sion, but read­out to come soon­er